Addressing Dual Disorders in a Medium-Term Admission Unit.
dual disorder
medium-stay unit
serious mental disorder
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
26 Dec 2021
26 Dec 2021
Historique:
received:
19
11
2021
revised:
22
12
2021
accepted:
24
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Due to the significant functional repercussions suffered by patients with dual disorder, we must evaluate which ones can benefit from intensive rehabilitative therapies in medium-stay psychiatric units. This was a retrospective study of patient medical records which intended to analyze sociodemographic and clinical variables and parameters related to the hospitalization and discharge of patients admitted to the Medium-Stay Unit (MSU) at the Castellón Provincial Hospital Consortium over 2 years (2017 and 2018), according to the presence or absence of dual disorders in these patients. Patients with a dual disorder represented 55.2% of the hospitalized patients. A higher proportion of them were male, were relatively younger, and had an earlier onset of mental illness, fewer associated medical pathologies, and shorter hospital admission times to the Short-Term Hospitalization Unit than those who did not present a dual disorder. A diagnosis on the schizophrenia spectrum with cannabis use or polyconsumption was the most common diagnosis; 98.2% of all the patients responded adequately to admission to the MSU. This work highlighted the need for higher doses of depot paliperidone in patients with dual disorders.
Identifiants
pubmed: 35053768
pii: brainsci12010024
doi: 10.3390/brainsci12010024
pmc: PMC8773554
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundación Hospital Provincial Castellón
ID : CAF 21-016 and CAF 21-017
Références
Curr Drug Abuse Rev. 2017;10(1):19-24
pubmed: 29065847
Clin Pract Epidemiol Ment Health. 2008 Oct 14;4:23
pubmed: 18854034
J Clin Psychiatry. 2006;67 Suppl 7:10-7
pubmed: 16961419
J Affect Disord. 2015 Jul 1;179:156-60
pubmed: 25863912
Adicciones. 2017 Jun 28;29(3):186-194
pubmed: 26990267
J Subst Abuse Treat. 2018 Dec;95:35-42
pubmed: 30352668
Can J Psychiatry. 2017 Nov;62(11):772-777
pubmed: 28655284
Eur Neuropsychopharmacol. 2019 Jan;29(1):32-45
pubmed: 30472164
Invest Clin. 2008 Jun;49(2):195-205
pubmed: 18717266
Psychiatr Pol. 2019 Dec 31;53(6):1237-1250
pubmed: 32017814
Can J Psychiatry. 2017 Sep;62(9):624-634
pubmed: 28886671
Eur Psychiatry. 2009 Oct;24(7):431-41
pubmed: 19783126
An Sist Sanit Navar. 2014 May-Aug;37(2):223-33
pubmed: 25189980
Epidemiol Psychiatr Sci. 2019 Feb;28(1):1-3
pubmed: 30060768
Rev Psiquiatr Salud Ment (Engl Ed). 2019 Apr - Jun;12(2):92-105
pubmed: 29954707
Schizophr Res. 2018 Jul;197:78-86
pubmed: 29117908
Gac Sanit. 2020 Mar - Apr;34(2):114-119
pubmed: 31053452
Psychiatr Danub. 2020 Sep;32(Suppl 1):70-74
pubmed: 32890366
Drug Alcohol Depend. 2018 Oct 1;191:234-258
pubmed: 30153606
Nord J Psychiatry. 2021 Jan;75(1):54-62
pubmed: 32720838
Actas Esp Psiquiatr. 2011 Mar-Apr;39(2):123-30
pubmed: 21404151
BMC Psychiatry. 2019 Feb 4;19(1):55
pubmed: 30717713
Actas Esp Psiquiatr. 2012 Sep-Oct;40(5):281-9
pubmed: 23076611
Adicciones. 2011;23(2):165-72
pubmed: 21647547
Curr Opin Psychiatry. 2012 May;25(3):194-200
pubmed: 22395768
Brain Sci. 2021 Aug 21;11(8):
pubmed: 34439720
J Neurosci Res. 2017 Jan 2;95(1-2):136-147
pubmed: 27870394
Acta Psychiatr Scand Suppl. 2003;(416):16-23
pubmed: 12755850
Int J Epidemiol. 2014 Apr;43(2):476-93
pubmed: 24648481
J Dual Diagn. 2014;10(2):84-90
pubmed: 25392250
Curr Opin Psychiatry. 2019 Jul;32(4):293-299
pubmed: 31157674